Can AI Detect Cancer? What Patients Need to Know About AI Cancer Detection in 2026

Where AI Cancer Detection Stands in 2026

Artificial intelligence has become one of the most rapidly evolving tools in cancer medicine. As of 2025, the FDA had approved approximately 873 AI-enabled medical devices, with radiology-based tools — many targeting cancer detection — making up the single largest category.¹ That number continues to grow.

It is important to distinguish between two types of AI cancer tools. Clinically approved tools have been evaluated for safety and efficacy and are actively used in hospitals and screening programs. Experimental tools are still under research or in limited trials and have not yet been cleared for routine clinical use. Consumer apps that claim to detect cancer fall into a third, often less regulated category, and should be interpreted with caution.

Understanding where a specific AI tool sits in this landscape is critical for patients. When you ask an AI doctor about a screening result, knowing whether the underlying tool is FDA-approved matters greatly.

Breast Cancer: AI Mammography Screening

AI breast cancer screening has produced some of the strongest clinical evidence to date. The landmark MASAI trial — a large randomized controlled trial conducted in Sweden — found that AI-supported mammography screening detected 6.4 cancers per 1,000 participants screened, compared to 5.0 per 1,000 in the standard double-reading control group.² That represents a 28% increase in cancer detection.

Crucially, the increase in detection did not come with a significant rise in false positives. The AI-supported group also achieved a 44% reduction in radiologist screen-reading workload, as AI allowed a single radiologist to replace the traditional two-reader system. Most of the additional cancers caught were small, lymph-node-negative invasive cancers — exactly the type of early-stage disease where treatment is most effective.²

A separate prospective population-based study in Sweden further confirmed that AI-supported reading was non-inferior to standard double reading in terms of cancer detection, while maintaining acceptable recall rates.³

You may want to ask your screening center whether they use AI-assisted mammography reading. Many programs in Europe and an increasing number in the United States are integrating these tools into their workflows.

Skin Cancer: AI Dermatology Tools

AI skin cancer diagnosis has also matured significantly. A systematic review of studies on AI-based melanoma detection found overall sensitivity (correctly identifying cancer) averaging around 91% and specificity (correctly ruling it out) around 94% for distinguishing melanoma from other melanocytic lesions.⁴ A separate real-world clinical trial found an AI decision support app achieved an area under the curve (AUROC) of 0.960, with sensitivity of 95.2% for melanoma identification in primary care.⁵

In 2023, the FDA cleared DermaSensor, a handheld AI-powered device that assists primary care clinicians in evaluating skin lesions for all three major skin cancers: melanoma, basal cell carcinoma, and squamous cell carcinoma. This represents a meaningful shift — bringing AI dermatology support to non-specialist settings where most patients first present with skin concerns.

However, limitations remain significant. Many AI skin cancer models were trained predominantly on images of lighter skin tones, which may reduce their accuracy for patients with darker skin. Research consistently highlights that external validation on diverse populations is lacking, and performance can vary widely depending on the quality and diversity of training data.⁴ This is a known issue being actively studied. For now, AI dermatology tools are best understood as decision support aids that assist clinicians rather than replace them.

For a broader look at how AI diagnosis accuracy by specialty compares across medical fields, including dermatology and radiology, our full breakdown covers the current evidence.

Lung Cancer: AI CT Screening

Low-dose computed tomography (CT) screening for lung cancer has been shown to reduce mortality in high-risk populations. AI is increasingly integrated into these programs to help radiologists identify and characterize pulmonary nodules — small spots on the lung that may require follow-up.

A systematic review of AI performance in lung cancer detection on CT found that AI models achieved sensitivity rates of 86% to 98%, compared to 68% to 76% for radiologists alone.⁶ AI also demonstrated advantages in classifying whether nodules were malignant, showing greater sensitivity and accuracy compared to radiologists in several analyses.⁶

The REALITY trial, a multicenter study involving over 1,100 patients across the U.S. and Europe, evaluated an AI algorithm for detecting and characterizing pulmonary nodules in low-dose CT — providing real-world evidence that these tools can function effectively in clinical environments beyond the research lab.

AI lung screening tools help reduce missed nodules and can flag findings that might otherwise require a second review. As with other modalities, these tools are integrated into radiologist workflows rather than operating independently.

What AI Cannot Do Yet

Despite the progress, AI cancer detection has important limitations that patients and clinicians must understand clearly.

AI cannot replace pathology or biopsy. Regardless of how confident an AI algorithm appears, a definitive cancer diagnosis still requires tissue examination by a pathologist. Imaging and AI screening can identify suspicious findings, but they cannot confirm cancer without a biopsy and histological analysis.

Training data bias is a documented problem. Research published in PMC found that standard deep learning models showed performance disparities in approximately 29.3% of diagnostic tasks when broken down by demographic factors such as race.⁷ Models have shown reduced accuracy for detecting certain cancers in African American patients, younger patients with breast cancer, and other underrepresented groups. This bias is not always apparent from published accuracy figures, which often reflect performance on majority populations.

AI struggles with rare cancers and unusual presentations. Most AI cancer models are trained on common cancer types with abundant data. Rare malignancies, atypical imaging appearances, and unusual clinical contexts fall outside the training distribution of many tools, making AI less reliable in these scenarios.

Clinical context is irreplaceable. AI analyzes images or data in isolation. It does not know your family history, current medications, recent lab results, or the nuances of your clinical examination. A radiologist or oncologist integrating an AI finding into your full clinical picture adds an essential layer of judgment that AI systems cannot replicate.

Understanding FDA AI health regulation helps clarify why these safeguards exist and what the approval process actually validates before a tool reaches clinical use.

What This Means for Patients

Artificial intelligence cancer screening is a genuine advance in early detection medicine, but it is a tool — one that functions best when paired with experienced clinical judgment.

Here is what the current evidence suggests for patients:

• Ask about AI at your screening appointment. Many breast imaging centers now use FDA-cleared AI tools to assist radiologists. Knowing whether AI is part of your screening workflow is a reasonable question.

• Do not rely on consumer skin cancer apps for diagnosis. While some clinically validated AI dermatology tools exist in medical settings, consumer apps are not equivalent and should not be used to make decisions about lesions. Consult a dermatologist or primary care provider.

• A positive or negative AI finding is not a diagnosis. AI flags patterns for clinical review. A radiologist, dermatologist, or oncologist still interprets those findings and orders follow-up as appropriate.

• Discuss your risk factors with your doctor. AI tools are most valuable as part of a structured screening program. Your eligibility for screening — for breast, lung, or skin cancer — depends on your individual risk profile, which a clinician is best positioned to assess.

• Know that AI accuracy varies. As detailed in AI diagnosis accuracy by specialty, performance is strong in some domains and more limited in others. The strength of evidence differs by cancer type.

When to See a Doctor

AI cancer detection tools are a complement to medical care, not a substitute for it. You should contact a healthcare provider promptly if you notice any of the following:

• A new lump or mass anywhere in your body that does not resolve within a few weeks

• Unexplained changes in a skin lesion — changes in size, color, shape, or texture, or a lesion that bleeds or does not heal

• Persistent cough, especially with blood, hoarseness, or unexplained shortness of breath

• Unexplained weight loss, fatigue, or night sweats that last more than a few weeks

• A screening result — whether AI-assisted or standard — that your provider recommends following up

These symptoms may indicate a wide range of conditions, and many have benign explanations. However, early evaluation gives you and your care team the best information to make decisions.

If you are unsure whether to seek care, tools like an AI doctor can help you think through your symptoms before or between appointments — but they are not a replacement for a clinical evaluation.

Conclusion

AI cancer detection represents a meaningful step forward in screening medicine. Clinical evidence supports AI breast cancer screening tools that catch more cancers with fewer false positives, AI dermatology aids with high accuracy for melanoma, and AI CT tools that improve detection of lung nodules. At the same time, limitations in training data diversity, the inability to replace pathology, and the absence of full clinical context mean that AI functions best as a tool that augments physicians rather than replaces them. If you have questions about whether AI-assisted screening is available or appropriate for you, a conversation with your doctor is the right starting point.

References

1. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. FDA. 2025. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices

2. Lund University / The Lancet Digital Health. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI). Lancet Digit Health. 2025. https://pubmed.ncbi.nlm.nih.gov/39904652/

3. Salim M, et al. Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health. 2023. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(23)00153-X/fulltext

4. Haenssle HA, et al. Performance of Artificial Intelligence in Skin Cancer Detection: An Umbrella Review of Systematic Reviews and Meta-Analyses. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/40745683/

5. Marchetti MA, et al. Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/38234043/

6. MDPI Healthcare. A Systematic Review of AI Performance in Lung Cancer Detection on CT Thorax. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12250385/

7. PMC / National Library of Medicine. Beyond the hype: Navigating bias in AI-driven cancer detection. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11546210/

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. The information presented here should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health, please seek immediate medical attention.